Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10591581 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL8041092 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL3213446 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL8040666 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL8035165 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL2674837 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL3222537 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL1643773 | 1.00 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL2528 | 0.98 | KCNA3 (0.76) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL7091202 | 0.95 | KCNA3 (0.73) | KCNA3TAAR1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010004016-A1 | USE OF PHENOXYALKYLAMINES IN COSMETIC AND/OR DERMATOLOGICAL COMPOSITIONS | L'OREAL (FR) | 2010-01-14 | — | — | WO | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
| US-6114534-A | REACTING A KETONE DERIVATIVE OF CARBAMOYL SUBSTITUTED HETEROCYCLE WITH PHOSPHORANE, FOLLOWED BY ACIDIFICATION TO FORM AN ANTICOAGULANT | ELI LILLY AND COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-6075147-A | OMEGA-PHENYL-OMEGA-(3-PYRIDYL)-OMEGA-ALKENOIC ACID DERIVATIVES BEARING A CARBAMOYL SUBSTITUTED OXAZOLYL OR OXAZOLINYL GROUP ON THE PHENYL RING IS USEFUL FOR THROMBOXANE RECEPTOR ANTAGONSIM OR THROMBOXANE SYNTHASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | disclosed |
| US-6031095-A | Intermediates in the preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5849922-A | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5849766-A | Carbamoyl substituted heterocycles | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0840725-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1998-05-13 | — | — | EP | disclosed |
| EP-0816361-A2 | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0811621-A2 | Carbamoyl substituted oxazoles as thromboxane receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997002242-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-01-23 | — | — | WO | disclosed |
| EP-0183147-A2 | Beta-substituted aminophenethylazol derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-06-04 | — | — | EP | disclosed |
| US-4323680-A | 4-Aminoquinazoline compounds useful as agricultural fungicides | SANKYO COMPANY LIMITED (JP) | 1982-04-06 | — | — | US | disclosed |
| US-4213987-A | 4-AMINOQUINAZOLINES | SANKYO COMPANY LIMITED (JP) | 1980-07-22 | — | — | US | disclosed |
| US-4053611-A | SUBSTITUTED PHENOXYALKYL QUATERNARY AMMONIUM COMPOUNDS AS ANTIARRHYTHEMIC AGENTS | THE DOW CHEMICAL COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | KCNA3 863/4885TAAR1 76/4885HDAC3 88/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | KCNA3 863/4885TAAR1 76/4885HDAC3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.